- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Mol Ther Nucleic Acids. 2014 Aug 19;3:e186. doi: 10.1038/mtna.2014.38.
The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo.
Lin SR1, Yang HC2, Kuo YT1, Liu CJ3, Yang TY1, Sung KC1, Lin YY4, Wang HY5, Wang CC5, Shen YC1, Wu FY1, Kao JH6, Chen DS6, Chen PJ6.
Author information
1Department of Microbiology, National Taiwan University College of Medicine, Taipei, Taiwan.
21] Department of Microbiology, National Taiwan University College of Medicine, Taipei, Taiwan [2] Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan [3] Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
31] Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan [2] Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan [3] Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
41] Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan [2] Department of Life Science, National Taiwan University College of Life Science, Taipei, Taiwan.
5Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
61] Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan [2] Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan [3] Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan [4] Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.
Abstract
Persistence of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) under current antiviral therapy is a major barrier to eradication of chronic hepatitis B (CHB). Curing CHB will require novel strategies for specific disruption of cccDNA. The clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system is a newly developed tool for site-specific cleavage of DNA targets directed by a synthetic guide RNA (gRNA) base-paired to the target DNA sequence. To examine whether this system can cleave HBV genomes, we designed eight gRNAs against HBV of genotype A. With the HBV-specific gRNAs, the CRISPR/Cas9 system significantly reduced the production of HBV core and surface proteins in Huh-7 cells transfected with an HBV-expression vector. Among eight screened gRNAs, two effective ones were identified. Interestingly, one gRNA targeting the conserved HBV sequence acted against different genotypes. Using a hydrodynamics-HBV persistence mouse model, we further demonstrated that this system could cleave the intrahepatic HBV genome-containing plasmid and facilitate its clearance in vivo, resulting in reduction of serum surface antigen levels. These data suggest that the CRISPR/Cas9 system could disrupt the HBV-expressing templates both in vitro and in vivo, indicating its potential in eradicating persistent HBV infection.
|
|